BASF supplies Maxomega™ EPA97 (Ethyl Icosapentate)
Leading the omega-3 pharma market
Over two decades ago, BASF introduced to the market Omacor®/Lovaza™, the first FDA and EU approved omega-3 based prescription drug. Our product is now represented in over 80 countries. We became world leaders in high-concentrate Omega-3 fatty acids for pharmaceuticals.
Leveraging world leading expertise, BASF is supplying Maxomega™ EPA97 (ethyl icosapentate), an ethylester oil.
Maxomega™ EPA97 (ethyl icosapentate) follows the specifications of the Japanese pharmacopoeia (JP).
- A well-established, global network of partners
- Unrivalled service expertise & experience in value chain management, regulatory services and quality management for pharmaceutical omega-3s
- A well-protected technology allowing for the environmentally-friendly production of Maxomega™ EPA 97 EE at exceptional purity levels
What we offer